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Abstract
In the present study, we tested the effect of OS (oxidative stress) inhibition in rats fed on an FRD [fructose-rich diet;
10% (w/v) in drinking water] for 3 weeks. Normal adult male rats received a standard CD (commercial diet) or an
FRD without or with an inhibitor of NADPH oxidase, APO (apocynin; 5 mM in drinking water; CD-APO and FRD-APO).
We thereafter measured plasma OS and metabolic-endocrine markers, AAT (abdominal adipose tissue) mass and
cell size, FA (fatty acid) composition (content and release), OS status, LEP (leptin) and IRS (insulin receptor
substrate)-1/IRS-2 mRNAs, ROS (reactive oxygen species) production, NADPH oxidase activity and LEP release by
isolated AAT adipocytes. FRD-fed rats had larger AAT mass without changes in body weight, and higher plasma
levels of TAG (triacylglycerol), FAs, TBARS (thiobarbituric acid-reactive substance) and LEP. Although no significant
changes in glucose and insulin plasma levels were observed in these animals, their HOMA-IR (homoeostasis model
assessment of insulin resistance) values were significantly higher than those of CD. The AAT from FRD-fed rats had
larger adipocytes, higher saturated FA content, higher NADPH oxidase activity, greater ROS production, a distorted
FA content/release pattern, lower insulin sensitivity together with higher and lower mRNA content of LEP and
IRS-1-/2 respectively, and released a larger amount of LEP. The development of all the clinical, OS, metabolic,
endocrine and molecular changes induced by the FRD were significantly prevented by APO co-administration. The
fact that APO treatment prevented both changes in NADPH oxidase activity and the development of all the
FRD-induced AAT dysfunctions in normal rats strongly suggests that OS plays an important role in the FRD-induced
MS (metabolic syndrome) phenotype.
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INTRODUCTION
According to some authors, the current epidemics of obesity,
Type 2 diabetes and the MS (metabolic syndrome) in the U.S.
[1] could be ascribed to the drastic increase in the annual per
capita fructose consumption [2,3]. It has also been shown that
administration of an FRD (fructose-rich diet) to normal rats in-
duces the development of features characteristic of the human
MS phenotype [4,5], and in humans it speeds up the transition
Abbreviations: AAT, abdominal adipose tissue; ACTB, β -actin; APO, apocynin; AU, arbitrary units; bw, body weight; CD, commercial diet; CT, threshold cycle value; DPI, diphenylene
iodonium; FA, fatty acid; FAME, fatty acyl methyl ester; FRD, fructose-rich diet; H&E, haematoxylin and eosin; HOMA, homoeostasis model assessment; H2DCF-DA,
2′,7′ -dichlorodihydrofluorescein diacetate; GLUT, glucose transporter; IGT, impaired glucose tolerance; IR, insulin resistance; IRS, insulin receptor substrate; KRB,
Krebs–Ringer–Bicarbonate; LEP, leptin; MDA, malondialdehyde; MS, metabolic syndrome; MUFA, mono-unsaturated FA; NBT, Nitro Blue Tetrazolium; NEFA, non-esterified FA; NEM,
N-ethylmaleimide; OS, oxidative stress; PKC, protein kinase C; PUFA, polyunsaturated FA; qRT-PCR, quantitative real-time PCR; ROS, reactive oxygen species; RT, reverse transcriptase;
SFA, saturated FA; TBARS, thiobarbituric acid-reactive substance; TAG, triacylglycerol.
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from IGT (impaired glucose tolerance) to Type 2 diabetes [6,7].
Consequently, the US Dietary Guidelines recommend limiting
calorie intake (which includes both added sugar and solid fat) to
13 % of energy requirement [8].
Although the precise mechanism whereby an FRD induces
the MS remains controversial, it has been postulated that an in-
creased rate of OS (oxidative stress) plays a key role [9–13].
In this regard, we have previously reported increased OS in
AAT (abdominal adipose tissue) [14] and impaired adipoinsular
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axis function [14,15] in normal rats fed on an FRD for
3 weeks.
Fructose is poorly or not metabolized by pancreatic β cells
[16,17]; however, it enhances the insulin secretion stimulated
by glucose [18]. Such enhancement could be probably mediated
through its effect upon digestive tract [19], liver [20] and adipose
tissue [21,22], with the consequent release of modulatory meta-
bolites and hormones/adipokines. In fact, the hypertriglycerid-
aemia and IR (insulin resistance) induced by the intake of an
FRD could account for such effects [14,15]. We further hypo-
thesized that all these alterations could be triggered by an initially
increased OS rate induced by excess fructose consumption [14].
In an attempt to provide an experimental support to our as-
sumption, we have studied the effect of the co-administration of
an FRD and an OS inhibitor, APO (apocynin) (a well-known in-
hibitor of NADPH oxidase) [23], upon: (i) serum concentrations
of OS, metabolic biomarkers and LEP (leptin); (ii) morphometric
characteristics of AAT adipocytes; (iii) fatty acyl composition,
OS biomarker levels and NADPH oxidase activity in AAT; (iv)
in vitro ROS (reactive oxygen species) production and LEP re-
lease by isolated AAT adipocytes; and (v) AAT mRNA level of
LEP and of intracellular mediators of insulin activity IRS (insulin
receptor substrate)-1/IRS-2.
MATERIALS AND METHODS
Animals and experimental design
Normal adult male Wistar rats were kept in a temperature-
controlled environment (23 ◦C) with a fixed 12 h light–dark cycle
and fed ad libitum for 1 week (stabilization period) with a stand-
ard CD (commercial diet; rat chow; Ganave). When the animals
reached 180–200 g of bw (body weight), they were randomly di-
vided into four groups and fed ad libitum for 3 weeks with (i) a
commercial standard chow and tap water (control diet; CD), (ii)
CD plus 10 % fructose (w/v; Cicarelli) in drinking water (FRD);
(iii) CD plus APO (Sigma; 5 mM in drinking water) [23] (CD-
APO) and (iv) FRD plus APO (FRD-APO). Although we have
shown previously that this FRD intake provides a comparable
total calorie intake in the study groups [15], we registered the
total daily energy intake and bw in all groups.
The study protocol complies with international regulations
concerning the ethical use and care of animals (Office of Animal
Care and Use, NIH).
Blood measurements
Non-fasting animals were killed between 08:30 and 09:00 h and
trunk blood was collected into EDTA-coated tubes. Tubes were
rapidly centrifuged (4 ◦C at 2060 g) and plasma samples were
immediately analysed or stored at − 20 ◦C. Commercial assay
kits were used to measure plasma levels of glucose (Bio Sys-
tem), TAG (triacylglycerol) (Wiener Laboratories) and NEFAs
[non-esterified FAs (fatty acids); Randox Laboratories]. Plasma
insulin concentration was determined by RIA [24] and lipid per-
oxidation by measuring TBARS (thiobarbituric acid-reactive sub-
stance) [14]. The amount of TBARS formed was calculated by
the extinction coefficient for the MDA (malondialdehyde)–TBA
complex of 1.56×105 (mol/l)− 1·cm− 1, and expressed as pmol
of MDA/mg of plasma protein, measured with the Bio-Rad Pro-
tein Assay kit. LEP concentration in plasma, in the incubation
medium samples as well as in AAT extracts was measured by
a validated specific RIA (standard curve 0.04–15 ng/ml) [25].
Intra- and inter-assay CV (coefficients of variation) of both these
RIAs were 3–7 % and 5–9 % respectively.
Histological studies
AAT pads were removed and immediately fixed in 4 % (v/v)
PFA (paraformaldehyde) (in 0.2 M phosphate buffer) at 4 ◦C for
a maximum of 3 days. Tissues were then washed with 0.01 M
PBS, immersed in 70 % (v/v) ethanol, and thereafter embedded
in paraffin. Sections of 4 μm were obtained at different levels
of the blocks and stained with H&E (haematoxylin and eosin).
Quantitative morphometric analysis was performed with a Je-
named 2 Carl Zeiss light microscope, an RGB CCD Sony camera
and OPTIMAS software (Bioscan Incorporated) (×40 objective).
For each AAT sample, one section and three levels were selected
(n= 4/5 animals per group). Systematic random sampling was
used to select ten fields for each section and a minimum of 100
cells per group were counted. We measured adipocyte diameter
and cell volume with the formula 4/3π .r3 [26].
Antioxidant system and TBARS in AAT
Pre-weighed ATT pads were sonicated in buffer containing
50 mM Tris/HCl (pH 7.4), 1.15 % (w/v) KCl, 1 mM NEM (N-
ethylmaleimide) and 0.1 % BHT (butylated hydroxytoluene), and
then centrifuged at 4 ◦C (600 g). Supernatants were stored at
− 70 ◦C under argon atmosphere. Contents of GSSG were de-
termined by HPLC [14], and GSH was measured as described
previously [14]. Samples for GSSG analyses were obtained in
the presence of NEM, and deproteinized using TCA (trichloro-
acetic acid; 15 % final concentration) [14]. The concentrations
of α-tocopherol, lycopene, retinol and β-carotene were determ-
ined by HPLC [14]. In addition, pre-weighed AAT pads were
immediately frozen in liquid N2. Tissues were homogenized in
a phosphate-buffered solution (pH 7.4) containing 10 % (w/v)
KCl; homogenates were stored at − 70 ◦C until processing for
measurement of lipid peroxidation as TBARS [14].
AAT pads and isolated adipocyte incubations
Small pieces (8–10 per tube, 100–200 mg) of AAT pads
from animals of each group were incubated in 1 ml of KRB
(Krebs–Ringer–Bicarbonate) buffer (118 mM NaCl, 25.96 mM
NaHCO3, 4.74 mM KCl, 2.24 mM CaCl2, 1.19 mM MgSO4 and
0.91 mM KH2PO4, pH 7.4), with 1 % essentially FA-free BSA
(Sigma), for 120 min at 37 ◦C in a 5 % CO2/95 % O2 atmosphere.
The spontaneous FA release into the media was then measured
as described previously [14].
Isolated adipocytes were obtained from AAT by a minor modi-
fication of the Rodbell procedure and processed as previously
reported by us [27]. Briefly, isolated adipocytes were diluted
with incubation medium to obtain a concentration of approx..
200 000 adipocytes/0.9 ml. Then this cell volume was distributed
in 15 ml conical plastic tubes and incubated for 45 min at 37 ◦C
in a 95 % O2/5 % CO2 atmosphere without (basal) or with insulin
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(0.1–10 nM; Novo Nordisk Pharma) [27]. At the end of the in-
cubation period, aliquots of medium were carefully separated and
kept frozen ( − 20 ◦C) to measure basal NEFAs as well as basal
and insulin-stimulated LEP concentrations. For this analysis, we
used samples taken from five different experiments (six replicates
per experiment).
AAT NADPH oxidase activity and intracellular ROS
production
Superoxide (O2 − ) generation was detected by NBT (Nitro Blue
Tetrazolium) assay [28], as described by Oliveira et al. [29].
Pre-weighed AAT pads were quickly rinsed in KRB buffer and
transferred into plastic tubes containing 500 μl of KRB buffer
with 1 % BSA, and incubated for 2 h with 0.2 % NBT (37 ◦C,
95 % O2/ 5 % CO2) in the presence of 3.3 mM glucose with or
without 10 μmol/l DPI (diphenylene iodonium), an NADPH
oxidase inhibitor. At the end of the incubation period, AAT
pads were sonicated in 100 μl of 50 % (v/v) acetic acid to
dissolve the NBT-reduced formazan; thereafter, the absorbance
of each sample was determined at 620 nm. The production of
O2 − ascribed to NADPH oxidase activity was expressed as the
difference between the values measured in the absence and the
presence of DPI in the reaction tube.
Intracellular oxidants were detected using H2DCF-DA (2′,7′-
dichlorodihydrofluorescein diacetate) [30]. Briefly, adipocytes
seeded in 12-well plates (at a density of 100 000 cells/well) were
incubated for 1 h at 37 ◦C in a 95 % O2/5 % CO2 atmosphere, in
the absence or presence of the PKC (protein kinase C) activator
PMA (10 μM), followed by a 30 min incubation with H2DCF-DA
(20 mM). After these treatments, cells were gently scraped by a
lifter and suspended in the same media. For detection of intracel-
lular fluorescence, cells were excited at 385 nm using a Beckman
Coulter fluorimeter. The dichlorofluorescein emission was recor-
ded at 535 nm and expressed in AU (arbitrary units) as net (PMA-
induced − spontaneous production) of the total ROS production.
Lipid composition analysis
Aliquots of AAT incubation medium or homogenates were pro-
cessed by GLC. Total lipids were extracted as previously de-
scribed [14]. GLC of FAME (fatty acyl methyl esters) was per-
formed as previously reported [14], except that in this case we
used a capillary column (Supelco) mounted on a Hewlett Packard
HP 6890 Series GC System Plus, equipped with a terminal com-
puter integrator system. FAMEs were identified by comparison of
their relative retention times with authentic standards, and mass
distribution was calculated electronically by quantification of the
peak areas. A mixture of pure authentic standards (Avanti Polar
Lipids) was routinely run to confirm the identity of the analytical
peaks. As already reported [14], the FAs determined were the
SFAs (saturated FAs) myristic (C14:0), palmitic (C16:0) and stearic
(C18:0) acids, the MUFAs (mono-unsaturated FAs) palmitoleic
(C16:1) and oleic (C18:1) acids, and the PUFAs (polyunsaturated
FAs) linoleic (C18:2 n− 6), eicosatrienoic (C20:3 n− 6), arachidonic
(C20:4 n− 6) and γ -linolenic (C18:3 n− 3) acids. When appropriate,
data were expressed as the relative composition of FAs (in μmol),
calculated as the percentage of the sum () of both SFA (SFA)
and UFA (unsaturated FAs) (UFA) from the sum of all FAs
measured in either AAT pads (content) or the incubation medium
(release). Additionally, relationships among different lipidic spe-
cies were also estimated (e.g. C18:2 n− 6/C20:4 n− 6).
AAT RNA isolation and qRT-PCR (quantitative
real-time PCR)
Total RNA was isolated from AAT pads of all experimental
groups by a modification of the single-step, acid guanidinium
isothiocyanate–phenol–chloroform extraction method (TRIzol®;
Invitrogen) [31]. The yield and quality of extracted RNA was
assessed by 260/280 nm absorbance ratio and electrophoresis in
denaturing conditions on 2 % (w/v) agarose gel. A total of 1 μg
of the total RNA was reverse-transcribed using random primers
(250 ng) and Superscript III RNase H-RT (reverse transcriptase;
200 units/μl: Invitrogen). For qRT-PCR the following primers
were applied: ACTB (β-actin) (R): 5′-ACCCTCATAGATGGG-
CACAG-3′, (F): 5′-AGCCATGTACGTAGCCATCC-3′ (115 pb)
(GenBank® accession number: NM_031144); LEP (R): 5′-CT-
CAGCATTCAGGGCTAAGG-3′, (F): 5′-GAGACCTCCTCC-
ATCTGCTG-3′ (192 bp) (GenBank® accession number:
NM_013076); IRS-1 (R): 5′-ACGGTTTCAGAGCAGAGG-
AA-3′, (F): 5′-TGTGCCAAGCAACAAGAAAG-3′ (176 bp)
(GenBank® accession number: NM_012969); IRS-2 (R): 5′-CC-
AGGGATGAAGCAGGACTA-3′, (F): 5′-CTACCCACTGA-
GCCCAAGAG-3′ (151 bp) (GenBank® accession number:
AF087674); and GLUT (glucose transporter)-4 (R): 5′-TGG-
ACGCTCTCTTTCCAACT-3′, (F): 5′-GCTTCTGTTGCCCTT-
CTGTC-3′ (166 bp) (GenBank® accession number:
NM_012751). A portion (2 μl) of the RT mix was amplified by
the QuantiTect Syber Green PCR kit (Qiagen), 0.5 mM of each
specific primer and the Light Cycler Detection System (MJ Mini
Opticon; Bio-Rad). PCR efficiency was approx. 1. CT (threshold
cycle value) was measured in separate tubes and in duplicate.
The identity and purity of the amplified product were checked
by electrophoresis on agarose mini gels, and the melting curve
was analysed at the end of amplification. Differences in CT were
calculated in every sample for each gene of interest as follows:
CT gene of interest −CT reporter gene. ACTB, whose mRNA
levels did not differ between control and test groups, was used as
a reporter gene. Relative changes in the expression level of one
specific gene (CT) were calculated as CT of the test group
minus CT of the control group, and then expressed as 2−CT .
Statistical analysis
Data were analysed by ANOVA (two-factor: diet and treatment),
followed by post-hoc comparisons with a Fisher’s test [32]. When
appropriate, the non-parametric Mann–Whitney test was used to
analyse data from adipose tissue mRNA expression [32]. Res-
ults are expressed as means +− S.E.M., and differences were con-
sidered significant when P values were <0.05.
RESULTS
Rat bw and energy intake
All experimental animals (10/12 rats per group) had com-
parable bw at the beginning of the experimental design (CD
group, 193.14 +− 3.01; CD-APO group, 197.11 +− 8.15; FRD
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Table 1 Circulating levels of several markers of the adipoinsular axis function, TBARS and HOMA index
Values are means +− S.E.M. (n= 8/10 rats per group). ∗P< 0.05 compared with CD; + P< 0.05 compared with FRD. FFA,
non-esterified ‘free’ fatty acid.
Diet
Parameter CD CD-APO FRD FRD-APO
Glucose (mM) 6.34 +− 0.14 5.96 +− 0.15 6.17 +− 0.21 6.07 +− 0.22
Insulin (ng/ml) 0.42 +− 0.03 0.45 +− 0.05 0.57 +− 0.07 0.41 +− 0.04
TAG (mM/100 g of bw) 0.42 +− 0.03 0.33 +− 0.05 0.62 +− 0.05∗ 0.32 +− 0.06+
FFA (mM/100 g of bw) 0.19 +− 0.01 0.21 +− 0.03 0.27 +− 0.02∗ 0.16 +− 0.03+
LEP (ng/ml per 100 g of bw) 1.64 +− 0.11 1.52 +− 0.18 2.17 +− 0.16∗ 1.47 +− 0.24+
TBARS (pmol/mg per ml) 58.72 +− 4.45 68.97 +− 4.45 73.71 +− 5.51∗ 67.10 +− 5.51+
HOMA-IR 2.981 +− 0.001 2.842 +− 0.009 5.271 +− 0.011∗ 2.673 +− 0.009+
group, 191.89 +− 4.22; FRD-APO group, 190.89 +− 5.49 g). At
3 weeks after the diet/treatment, rats from the CD and FRD
groups also showed comparable bw values (292.83 +− 9.14
and 302.33 +− 5.19 g respectively), whereas those co-treated
with APO had lower but not significantly different values
(274.67 +− 8.04 and 279.17 +− 9.59 g in the CD-APO and FRD-
APO groups respectively). A comparable individual daily en-
ergy intake was registered over the 3-week experimental period
in all animals, regardless of treatment and diet (21-day aver-
age): CD group, 108.76 +− 8.65 kJ/day per 100 g of bw; CD-
APO group, 107.68 +− 12.04 kJ/day per 100 g of bw; FRD
group, 121.79 +− 14.25 kJ/day per 100 g of bw; FRD-APO group,
118.79 +− 12.46 kJ/day per 100 g of bw.
Circulating biomarker levels and HOMA
(homoeostasis model assessment) score
Lipids and OS biomarker
Rats fed on the FRD had significantly higher plasma concentra-
tions of TAG, NEFAs and TBARS compared with CD-fed rats
(Table 1; P< 0.05). APO administration to FRD-fed rats effect-
ively prevented all these increments (Table 1).
Adipoinsular axis function and HOMA score
Although FRD administration did not significantly modify the cir-
culating levels of glucose and insulin, these levels showed an in-
creasing trend (Table 1). Conversely, significantly higher HOMA
values were measured in FRD-fed rats (P< 0.05), together with
a significant increase in the circulating levels of LEP (P< 0.05
compared with CD-fed rats; Table 1). Co-administration of APO
to these rats significantly prevented both the higher HOMA values
and the increased plasma LEP levels (P< 0.05; Table 1).
AAT mass and adipocyte characteristics
AAT mass was significantly larger in FRD- than in CD-fed
rats (2.48 +− 0.17 compared with 1.87 +− 0.21 g; n= 8/10 rats per
group; P< 0.05). Such a difference was no longer observed in
APO-treated rats (1.83 +− 0.21 and 1.97 +− 0.23 g in CD-APO and
FRD-APO groups respectively; n= 8/10 rats per group).
AAT adipocytes from FRD-fed rats were significantly lar-
ger (in diameter and volume) than adipocytes from CD-fed rats
(P< 0.05; Figures 1E and 1F respectively). In FRD-APO-fed
rats, adipocyte size and volume were similar to those observed
in CD-fed rats, whereas no changes were observed in cells from
CD-APO-fed rats (Figures 1E and 1F).
AAT non-enzymatic antioxidant defence system and
TBARS content
Although the total GSH content of the AAT homogenate was
not modified by the FRD, this diet significantly increased and de-
creased (compared with CD values) GSSG and GSH respectively
(Table 2). Consequently, the GSH/GSSG ratio decreased signific-
antly in FRD-fed animals. Similarly, the lipid-soluble antioxid-
ants measured as the content of α-tocopherol (the amount of the
γ -isomer was negligible), β-carotene, retinol and lycopene were
also significantly lower in FRD- than in CD-fed rats (Table 2).
Concomitantly, the TBARS concentration was significantly
higher in FRD- than in CD-fed rats (Table 2). Taken together,
these changes demonstrate that the FRD induced a significant de-
crease of the non-enzymatic antioxidant system in AAT. Although
APO co-administration did not introduce significant changes in
CD-fed rats, it significantly improved the antioxidant capacity of
AAT in FRD-fed rats (Table 2).
Analysis of AAT fatty acyl composition and release
into the incubation medium
The FA composition of extracted lipids from AAT pads is
shown in Table 3. FRD administration did not modify the pro-
portion of the saturated myristic acid; however, it significantly
increased the proportion of other SFAs (palmitic and stearic
acids). Moreover, this diet induced an overall enhancement of
SFA (SFA) (P< 0.05 compared with CD values). Although
longer chain PUFA (>C20 species) were minimally detected in
CD pads, they became undetectable in pads from FRD-fed an-
imals. The amount of summed MUFAs (MUFA) and grouped
PUFAs (PUFA) was significantly reduced in pads from FRD-
fed rats (P< 0.05 compared with CD values). Both the C18:2
n − 6/C20:4 n − 6 and C20:3 n − 6/C20:4 n − 6 ratios were not modified
by the FRD. A detrimental metabolic effect of such a diet was
also observed after analysing the ratios of both summed SFAs
to MUFAs and PUFAs (SFA/MUFA and SFA/PUFA re-
spectively). Indeed, such ratios were drastically increased by this
diet (P< 0.05 compared with CD values; Table 3). It should also
be noted that co-administration of APO to FRD-fed rats resulted
in the full prevention of the deleterious FRD effect on AAT fatty
acyl composition (Table 3).
The qualitative profile of FAs released by incubating AAT
pads was quite similar to that found in tissue contents (Table 4).
Although myristic acid was released only in traces (or even at
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Table 2 Total glutathione, GSH, GSSG, non-enzymatic antioxidants and TBARS in AAT pads from the different experimental
groups
Values are means +− S.E.M. (n= 5 pads per group). ∗P< 0.05 compared with CD; + P< 0.05 compared with FRD.
Group
Parameter CD CD-APO FRD FRD-APO
Total GSH (nmol/g) 35.6 +− 0.75 34.2 +− 0.61 36.8 +− 0.45 38.61 +− 0.69
GSH (nmol/g) 31.15 +− 0.55 30.11 +− 0.49 27.78 +− 0.35∗ 31.94 +− 0.62+
GSSG (nmol/g) 4.45 +− 0.15 4.09 +− 0.11 9.02 +− 0.25∗ 6.66 +− 0.22+
GSH/GSSG 7.01 +− 0.11 7.28 +− 0.15 3.09 +− 0.05∗ 5.82 +− 0.09+
Retinol (μg/g) 0.56 +− 0.02 0.58 +− 0.06 0.22 +− 0.02∗ 0.41 +− 0.08+
β -Carotenoids (μg/g) 1.15 +− 0.06 0.99 +− 0.05 0.78 +− 0.03∗ 1.19 +− 0.04+
α-Tocopherol (μg/g) 202.5 +− 5.15 222.1 +− 4.80 174.4 +− 2.95∗ 197.3 +− 3.15+
Lycopenes (μg/g) 0.31 +− 0.04 0.29 +− 0.06 0.21 +− 0.03∗ 0.33 +− 0.04+
TBARS (nmol MDA/mg of AAT protein) 22.13 +− 3.51 20.32 +− 5.81 50.51 +− 7.99∗ 15.35 +− 4.33+
Figure 1 FRD-induced adipocyte hypertrophy
Representative fields of AAT from CD- (A), FRD- (B), CD-APO- (C) and FRD-APO- (D) fed rats stained with H&E. Scale bar
represents 50 μm; magnification ×400). Adipocyte diameter (E) and volume (F) in AAT pads from the different groups
are also shown. Results are means +− S.E.M. (n= 4/5 rats per group). ∗P< 0.01 compared with CD; + P< 0.01 compared
with FRD.
undetectable levels) by AAT pads from different origins, palmitic
and stearic acid release was higher in FRD-fed than in CD-fed
rats (P< 0.05); the same profile was recorded when SFAs were
grouped (SFA). On the other hand, the AAT pad release of oleic
acid and other unsaturated FAs (linoleic, γ -linolenic, eicosatri-
enoic and arachidonic acids, and longer FAs) by AAT pads
from FRD-fed rats was significantly reduced (P< 0.05 compared
with CD values). Concomitantly, the amount of grouped MUFAs
(MUFA) and PUFAs (PUFA) was also decreased. Similar to
the changes recorded in the FA composition of pads, the analyt-
ical ratios C18:2 n− 6/C20:4 n− 6 and C20:3 n− 6/C20:4 n− 6 were signi-
ficantly higher in the incubation medium of FRD pads (P< 0.05
compared with CD values). These ratios indirectly reflect the con-
version rate of the precursor (C18:2 n− 6) into the other members of
the n− 6 essential FA family accomplished by the 6 and 5 de-
saturases. In agreement with these data, a significant increase in
the SFA/PUFA ratio was observed after the analysis of AAT
pads from FRD-fed rats (P< 0.05 compared with CD values).
The beneficial effect of APO co-administration to FRD-fed rats
was also evident at the level of the incubation medium of their
AAT pads. Thus these findings clearly indicate that APO could
prevent the FRD-induced changes of fatty acyl chains in complex
lipids of the AAT (Tables 3 and 4).
Effectiveness of APO treatment on AAT NADPH
oxidase activity
NADPH-oxidase-dependent O2 − production was significantly
higher in AAT pads from FRD- than from CD-fed rats (P< 0.05;
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Table 3 FA content of AAT pads from the different experimental groups
Various sums () and ratios are also shown. Values are means +− S.E.M. (n= 5 pads per group from three or four experiments).∗P< 0.05 compared with CD values; + P< 0.05 compared with FRD values.
Group
FA content (μmol/mg of tissue) CD CD-APO FRD FRD-APO
C14:0 2.2 +− 0.1 2.0 +− 0.1 2.6 +− 0.2 2.0 +− 0.1+
C16:0 30.3 +− 1.5 29.6 +− 1.1 35.3 +− 1.4∗ 31.6 +− 1.2
C16:1 1.8 +− 0.1 1.5 +− 0.1 1.5 +− 0.06∗ 2.0 +− 0.1+
C18:0 22.2 +− 1.0 23.3 +− 1.1 26.3 +− 0.8∗ 23.5 +− 0.6+
C18:1 12.0 +− 0.7 11.9 +− 0.5 10.2 +− 0.5 12.3 +− 0.2+
C18:2 n− 6 18.0 +− 0.7 17.3 +− 0.8 16.6 +− 0.8 17.8 +− 0.4
C18:3 n− 3 0.9 +− 0.03 0.8 +− 0.03 0.5 +− 0.05∗ 0.8 +− 0.1+
C20:3 n− 6 0.8 +− 0.01 0.7 +− 0.02 0.8 +− 0.03 0.9 +− 0.05
C20:4 n− 6 23.5 +− 1.1 24.3 +− 1.0 17.3 +− 0.9∗ 24.8 +− 0.8+
>C20 PUFAs 0.1 +− 0.01 <0.10 <0.10 0.1 +− 0.03
SFAs 54.7 +− 2.3 54.9 +− 2.0 64.6 +− 1.9∗ 57.1 +− 1.9+
MUFAs 13.8 +− 0.8 13.4 +− 0.8 11.7 +− 0.6 14.3 +− 0.9
SFAs/MUFAs 4.0 +− 0.1 4.1 +− 0.05 5.5 +− 0.1∗ 4.0 +− 0.01+
C18:2 n− 6/C20:4 n− 6 0.8 +− 0.05 0.7 +− 0.05 1.0 +− 0.1 0.7 +− 0.03
C20:3 n− 6/C20:4 n− 6 0.03 +− 0.01 0.03 +− 0.01 0.05 +− 0.02 0.04 +− 0.01
PUFAs 25.2 +− 0.6 25.8 +− 0.8 18.6 +− 0.4∗ 26.5 +− 0.9+
SFAs/PUFAs 2.2 +− 0.1 2.1 +− 0.05 3.5 +− 0.1∗ 2.2 +− 0.1+
Table 4 FA release by incubated AAT pads from different groups
Various sums () and ratios are also shown. Values are means +− S.E.M. (n= 5 pads per group per experiment from three or
four experiments). ∗P< 0.05 compared with CD values; + P< 0.05 compared with FRD values.
Group
FA release (μmol/l of medium) CD CD-APO FRD FRD-APO
C14:0 <0.10 0.10 +− 0.005 <0.10 0.10 +− 0.015
C16:0 4.10 +− 0.05 3.20 +− 0.10 5.50 +− 0.05∗ 3.90 +− 0.05
C16:1 <0.10 <0.10 <0.10 0.10 +− 0.01
C18:0 6.20 +− 0.05 5.80 +− 0.10 8.30 +− 0.10∗ 6.20 +− 0.15
C18:1 <0.10 0.20 +− 0.01 <0.10 0.1 +− 0.015
C18:2 n− 6 1.50 +− 0.10 1.30 +− 0.10 0.70 +− 0.05∗ 1.30 +− 0.05
C18:3 n− 3 0.10 +− 0.0015 0.10 +− 0.005 <0.10 0.10 +− 0.02
C20:3 n− 6 <0.10 0.10 +− 0.015 <0.10 <0.10
C20:4 n− 6 0.20 +− 0.05 0.30 +− 0.02 <0.10 0.20 +− 0.015
>C20 PUFAs 0.20 +− 0.02 0.20 +− 0.025 <0.10 0.10 +− 0.005
SFA 10.30 +− 0.10 9.1 +− 0.21 13.80 +− 0.15∗ 10.2 +− 0.22+
MUFA 0.18 +− 0.05 0.25 +− 0.03 0.16 +− 0.04 0.20 +− 0.03
SFA/MUFA 57.78 +− 3.31 36.4 +− 1.90 86.75 +− 4.47∗ 51.00 +− 3.45+
C18:2 n− 6/C20:4 n− 6 7.50 +− 0.31 4.33 +− 0.22 18.75 +− 1.11∗ 6.50 +− 0.31+
C20:3 n− 6/C20:4 n− 6 0.40 +− 0.11 0.33 +− 0.05 2.50 +− 0.26∗ 0.40 +− 0.03+
PUFA 2.00 +− 0.17 2.2 +− 0.18 0.70 +− 0.05∗ 1.9 +− 0.12+
SFA/PUFA 5.15 +− 0.59 4.14 +− 1.17 19.70 +− 3.00∗ 5.37 +− 1.83+
Table 5). In AAT from APO co-treated rats the NADPH-oxidase-
dependent O2 − production was drastically reduced regardless of
the diet administered. In fact, anion production by AAT pads
from CD-APO-fed rats was significantly lower than in APO-
untreated CD-fed rats (P< 0.05). Moreover, APO co-treatment
fully prevented the FRD-induced O2 − production (Table 5). It
has to be stressed that the profile of total AAT O2 − production
followed a similar pattern to that of NADPH oxidase activity
(results not shown).
Isolated adipocyte ROS production and LEP
secretion: effects of APO treatment
PMA-induced net ROS production in vitro was significantly
higher in AAT adipocytes isolated from FRD-fed rats than in
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Figure 2 FRD-induced changes in adipocyte OS and adipokine production
PMA-elicited AAT isolated adipocyte ROS production in different experimental groups (left-hand panel). The effect of
increasing concentrations of insulin (0–10 nM) on LEP release by isolated adipocytes from AAT pads of the different
groups is also shown (right-hand panel). Values are means +− S.E.M. (n= 4 different experiments, six replicates per
condition). ∗P< 0.05 compared with CD, aP< 0.05 compared with 0 nM insulin; bP< 0.05 compared with 0.1 nM insulin;
+ P< 0.05 compared with the CD, CD-APO and FRD-APO groups under a similar condition.
Table 5 NADPH oxidase activity (measured as O2 −
production) measured in AAT from CD, CD-APO, FRD and
FRD-APO rats
Values are means +− S.E.M. from three different experiments (n= 5
pads per group) and represent the difference between the O2 − value
measured in the absence and presence of DPI in the incubation me-
dium. ∗P< 0.05 compared with CD; + P< 0.05 compared with FRD.
Group AAT O2 − production (AU)
CD 101.09 +− 7.86
CD-APO 69.43 +− 5.68∗
FRD 179.04 +− 15.28∗
FRD-APO 75.98 +− 6.11∗ +
those from CD-fed rats (P< 0.05; Figure 2, left-hand panel).
This increased ROS production was markedly reduced in rats
co-treated with APO, regardless of the diet received (P< 0.05
compared with CD values; Figure 2, left-hand panel).
AAT adipocytes isolated from all the experimental groups and
incubated with increasing concentrations of insulin (0–10 nM) re-
leased LEP in a concentration-dependent fashion (Figure 2, right-
hand panel). At any condition tested, adipocytes from FRD-fed
rats released a significantly higher amount of LEP than those
from CD-fed rats (P< 0.05 compared with CD values). Further-
more, the threshold for insulin-induced LEP release by adipo-
cytes from FRD-fed rats shifted to the right, thus showing de-
creased insulin sensitivity. In fact, in FRD-fed rats a signific-
ant increase in LEP release (P< 0.05 compared with baseline)
started at a 100 times greater insulin concentration (10 com-
pared with 0.1 nM) than in adipocytes from CD-fed rats. APO
co-administration did not affect LEP release by adipocytes from
Figure 3 LEP, IRS-1 and IRS-2 mRNA levels in AAT pads from CD-
and FRD-fed rats without or with APO treatment
Results (expressed in AU) are normalized to the levels of ACTB and
then presented as relative to values obtained in AAT pads from CD-fed
rats. Results are means +− S.E.M. (n= 5 pads per group). ∗P< 0.05
compared with CD; + P< 0.05 compared with FRD.
CD-fed rats, but it reduced the high LEP release by adipocytes
from FRD-fed rats to values comparable with those of adipo-
cytes from CD-fed rats and re-established the normal threshold
of insulin-induced LEP release (Figure 2, right-hand panel).
mRNA content of LEP and intracellular insulin
mediators in AAT
The mRNA content of LEP in AAT pads was significantly higher
in FRD- than in CD-fed rats (P< 0.05; Figure 3, left-hand panel).
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Although APO administration to CD-fed rats did not modify such
content (compared with CD-fed rats), it abolished the enhance-
ment observed in FRD pads.
IRS-1 and IRS-2 mRNA contents were significantly lower in
AAT from FRD- compared with CD-fed rats (P< 0.05; Fig-
ure 3, middle and right-hand panels respectively). APO co-
administration fully prevented the detrimental effect of the FRD
on these two intracellular insulin mediators (P< 0.05). Addition-
ally, neither treatment- nor diet-dependent changes were found in
AAT GLUT-4 mRNA content (results not shown).
DISCUSSION
The results of our present study support the reliability of the
FRD-fed rat model to induce several metabolic and endocrine
dysfunctions [14,15] that resemble those present in the human
MS phenotype [4–6,33]. These are characterized by high val-
ues of the HOMA index (indicative of an IR state) and elevated
plasma levels of lipids (TAG and NEFAs), adipokines (LEP) and
OS biomarkers (specifically TBARS) that indicate increased lipid
peroxidation. Thus the model results in a useful tool to study the
pathogenesis of the dietary-induced MS and test the effectiveness
of different prevention/treatment strategies. The abnormally high
levels of these biomarkers confirm those reported in different
studies [4–6,14,15,34], as well as their association with several
metabolic/endocrine dysfunctions, such as impaired insulin sens-
itivity, IGT and abnormal lipid metabolism. In the present study,
however, we have selectively focused our attention on the meta-
bolic/endocrine AAT dysfunction and the role played by the local
and peripheral OS increase. To assess this role, and in order to
establish a pathogenic event sequence, we administered an FRD
together with APO, an effective inhibitor of NADPH oxidase
activity [23].
Brownlee [35] has shown that the excessive provision of a
metabolic substrate (fructose in our case) enhances mitochon-
drial ROS production, which results in a decreased antioxidant
defence mechanism, increased PKC isoform activities (mech-
anism driving to tissue impaired insulin signalling), enhanced
adipokine production and promotion of high non-enzymatic glyc-
osylation rate. The high ROS production and TBARS concen-
tration demonstrate the increased OS in the AAT of our FRD-
fed rats. This process would simultaneously trigger several dys-
functions, namely, decreased non-enzymatic antioxidant defence
([14], and the present results) and insulin sensitivity, a higher re-
lease of FAs, and a significant elevation of the SFA/UFA
ratio [14]. The high release of FAs with the consequent in-
crease of their circulating levels would stimulate NADPH ox-
idase activity [36], establishing a positive-feedback mechan-
ism that would maintain a higher ROS production. In fact, we
found that a 3-week FRD intake resulted in a local (AAT) en-
hancement in NADPH oxidase activity, which tightly paralleled
both the increased AAT ROS production and plasma TBARS
levels. Moreover, co-administration of FRD and APO signific-
antly prevented all these FRD-induced changes. Interestingly,
the NADPH oxidase inhibitor treatment was an effective se-
quential corrector of the AAT NADPH oxidase activity/ROS
production firstly and, thereafter, of most of the metabolic and
AAT dysfunctions that occur after feeding the animals with the
FRD.
Curtis et al. [37] recently suggested that protein carbonyla-
tion (due to the increased OS ratio) plays a major role in mito-
chondrial dysfunction and may be linked to the development
of IR in the adipocyte. Thus this mechanism could contrib-
ute to the IR state present in the AAT of FRD-fed rats. The
fact that adipose tissue of markedly obese insulin-resistant in-
dividuals shows lower AMPK (AMP-activated protein kinase)
and higher OS values than insulin-sensitive patients [38] lends
further support to the usefulness of the FRD-fed rat model to
study the intrinsic mechanisms of AAT dysfunctions and their
relationship with Type 2 diabetes development. Complementar-
ily, the high levels of tissue ROS, plasma FAs, NF-κB (nuclear
factor κB) and other pro-inflammatory transcription factors [39]
may also contribute to the transition from the state of IGT to
Type 2 diabetes in rats chronically fed on a high-carbohydrate diet
[40].
The link between insulin sensitivity and FA composition was
reported early on by Borkman et al. [41], showing that decreased
insulin sensitivity was associated with decreased concentrations
of PUFAs in skeletal-muscle phospholipids, thus suggesting that
changes in FA composition in this tissue modulate the hormone’s
action. This relationship was also shown in adipose tissue ([14]
and the present results).
The biosynthesis of high PUFAs is mainly modulated by the
6 and 5 desaturases through dietary and hormonal stimu-
lated mechanisms, and insulin activates both enzymes [42]. Con-
sequently, the lower insulin sensitivity present in the AAT of
FRD-fed rats (demonstrated by the lower IRS-1/IRS-2 expres-
sion and the decreased insulin-induced LEP release) could ex-
plain their high SFA/UFA ratio. Since enhanced OS could
also inhibit 5 and/or 6 desaturase activities/y [43], such an
effect would contribute to increase this particular ratio. Further-
more, the decreased β-cell mass present in these rats due to the
OS-induced apoptotic rate [44] would actively contribute to the
lower insulin effect.
Concurrent with the impaired lipid metabolism, AAT from
FRD-fed rats underwent profound changes in its mass (enlarged),
cell morphology (increased adipocyte size/volume) and expres-
sion of adipokines (enhanced LEP mRNA content) and intracel-
lular insulin mediator (decreased IRS-1/IRS-2 mRNAs) genes.
The presence of large adipocytes has been associated with LEP
overproduction [45], as shown by data reproduced in our model
both under in vivo and in vitro conditions, as well as with its
higher gene expression. It is known that LEP significantly af-
fects insulin binding to its receptor [46] and the expression of
IRS-1/IRS-2 downstream of the insulin receptor [47,48]. These
LEP effects reinforce the concept that the AAT tissue dysfunc-
tion plays a relevant role in the development of the overall IR
observed in FRD-fed rats (high HOMA values).
The development of all the morphological, metabolic and en-
docrine dysfunctions previously described was effectively pre-
vented by co-administration of APO with the FRD. APO is
a highly effective inhibitor of the NADPH oxidase system by
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interfering, at least in part, with the assembly of cytosolic ele-
ments of the enzyme at the cell membrane level [49–51]. As
a result, catalytic transmembrane proteins cannot reach com-
plete enzyme functionality [52], thus reducing ROS production.
Consequently, this preventive effect strongly plays in favour of
our departing hypothesis that OS is the first and main cause of
the FRD-induced human MS-like phenotype in normal rats. We
cannot, however, discard that some beneficial effects of APO
can be partly ascribed to its NADPH-oxidase-independent action
[53].
In brief, the result of the present study show that adminis-
tration of an FRD for 3 weeks to normal rats induces multiple
morphological, metabolic and endocrine alterations whose de-
velopment can be effectively prevented by inhibiting the main
enhancer of endogenous OS, NADPH oxidase activity, with the
highly effective inhibitor APO. These results could help to better
understand the pathogenesis of these alterations and also suggest
that the use of such an inhibitor could help to prevent, at least in
rats, the development of dietary-induced MS.
CLINICAL PERSPECTIVES
 The current epidemics of obesity, Type 2 diabetes and the
MS could be ascribed to the drastic increase in fructose con-
sumption. On the other hand, administration of an FRD to
normal rats induces the development of the human-like MS
phenotype. The increased rate of OS and an associated AAT
dysfunction would play a key role in this process.
 In the present study, we have shown that normal rats fed on an
FRD for 3 weeks have larger AAT mass and multiple meta-
bolic and endocrine alterations whose development can be
effectively prevented by inhibiting the main enhancer of en-
dogenous OS, NADPH oxidase activity, with a highly effective
inhibitor (APO).
 These results could help to better understand the pathogenesis
of these alterations, and this knowledge would facilitate the
development of treatment and preventive strategies for dietary-
induced MS.
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